<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Food and Drug Administration policy being considered for new marketed <z:chebi fb="0" ids="35679">hypolipidemic agents</z:chebi> includes: long-term safety to be demonstrated in postmarketing studies; evidence of clinical effectiveness to be demonstrated within a specified time period </plain></SENT>
<SENT sid="1" pm="."><plain>Effectiveness is to be judged by one or more of the following: reduction in <z:hpo ids='HP_0000991'>xanthomata</z:hpo>, reduction atherosclerotic plaque, reduction in morbidity of <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> or peripheral and cerebral <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, and reduction in mortality </plain></SENT>
<SENT sid="2" pm="."><plain>Randomized double blind trials are deemed necessary </plain></SENT>
</text></document>